October 30 | 2012


Vienna, October 2012 – Andreas Hauer, an experienced manager with strong finance background joins Savira pharmaceuticals, an Austrian biotech company focusing on the development of novel anti-influenza drugs.


“It is a great pleasure to welcome Andreas Hauer in our team”, said Oliver Szolar, CEO of Savira. “Andreas combines biotech industry experience, management, and financial skills that will help Savira achieve its ambitious goals”. “With Andreas in the team, we now have financial know-how that is commensurate with the needs of our development activities” added Helmut Buschmann, CSO of Savira.

Andreas Hauer has 16 years of experience in financial services, management consultancy, and biotechnology industry with particular strengths in corporate finance. Andreas Hauer joins Savira after heading a department in Erste Group Bank’s Group Corporate and Investment Banking division. From 2001 to 2008 Andreas held various management positions in Vienna-based biotech companies – starting in 2001 at igeneon until after its acquisition by NASDAQ-listed Aphton Corp in 2005, subsequently as external CFO and advisor to a number of VC and private capital-backed biopharmaceutical companies (including Fibrex, Nabriva, and onepharm). As graduate of the Institut d’ Etudes Politiques de Paris and holding a masters degree in business studies from Hochschule St. Gallen, he started his career with Morgan Stanley’s Investment Banking Division in London as an analyst before joining the Boston Consulting Group as a consultant.

“Savira offers me the chance to contribute to a unique growth story built on the development of novel influenza therapeutics. I am very glad to become part of such a strong and committed team embedded in a network of top league collaborating partners”, commented Andreas Hauer on his appointment as CFO of Savira pharmaceuticals.


About Savira

Savira pharmaceuticals GmbH – based in Vienna, Austria – is focusing on the design of novel, innovative influenza therapeutics using a rational, structure-based drug development approach. Savira follows the biotech business model, turning capital and public grants into the preclinical and clinical development of a portfolio of anti-influenza drug candidates. Savira thus strives to create a sustainable pipeline, generate value for shareholders, improve quality of life for people suffering from influenza, and add to the arsenal of antivirals thus improving influenza pandemic preparedness. In May 2012 Savira signed a Collaboration and License Agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY).



Savira pharmaceuticals GmbH
Oliver Szolar, CEO
Veterinärplatz 1/IA
A-1210 Vienna
Phone: +43 1 25077 5904
Fax: +43 1 25077 5999


Klick to download PDF: 20121025 Savira-Press release.pdf